

**Title: Shoulder Symptom Irritability Scale: A Single-Blinded Observational Study (SSIS)**

**Identifier: NCT02995941**

**Date of Document: October 31, 2016**

## 1 STUDY PROTOCOL with SAP & ICF

## 2

### 3 **Section A: Experimental Design**

4 This study will employ a quasi-experimental design utilizing repeated measures (specific  
5 aim 1), followed by cross-sectional analysis (specific aims 2 and 3). The target sample size for  
6 the study will be 25 physical therapists and 90 patients. Patient-reported outcome measures were  
7 selected based upon their reliability, validity and internationally accepted use. Given that there is  
8 no single universal patient reported outcome measure for the shoulder, multiple measures will be  
9 utilized during the third aim of this project.

#### 10 Specific Aim 1

11 The first specific aim will be to determine the reliability of the shoulder symptom  
12 irritability classification scale. To address this aim, the project will analyze paired rater  
13 judgments of shoulder symptom irritability (high, moderate or low) from 90 patients with  
14 shoulder pain. Raters will be physical therapists from multiple clinics trained in rating shoulder  
15 symptom irritability. Prevalence-adjusted, bias-adjusted Kappa for ordinal scales (PABAK-OS)<sup>1</sup>  
16 will be the primary measure of reliability. However, analysis may be adjusted based on the data  
17 distribution.

#### 18 Specific Aim 2

19 The second aim is to compare level of functional limitation between shoulder symptom  
20 irritability groups. To address this aim, the project will analyze patient-reported functional  
21 measures using analysis of variance with post-hoc analysis to compare functional disability  
22 across different levels of shoulder symptom irritability. The independent variable will be the  
23 shoulder symptom irritability level, and dependent variables will include patient-reported  
24 functional status measures. The hypothesis is that patients with higher irritability will report  
25 greater functional deficits.

#### 26 Specific Aim 3

27 The final specific aim is to determine if the level of shoulder symptom irritability dictates  
28 the chosen intervention intensity. To address this aim, raters will select planned intervention  
29 choices for each of the 90 patients, utilizing a pre-specified list of possible physical therapy  
30 interventions. Data analysis will include PABAK-OS for correlation, and independent t-test for  
31 differences between clinical specialist and non-specialist groups. The hypothesis is that patients  
32 with high irritability will be prescribed interventions aimed at minimizing the physical stress to  
33 the affected tissue(s), while patients with low irritability will be prescribed interventions at a  
34 higher intensity to address the physical impairments.

### 35 **Section B: Subjects**

#### 36 1. Number of subjects

37 Raters will be recruited from outpatient physical therapists in the St. Luke's  
38 University Health Network with an expected response of 25. Patient subjects will be  
39 recruited from a convenience sample of consecutive patients presenting for physical

therapy consultation for shoulder pain. Expected patient sample size is 90 subjects over a 6-month period. As pilot data has demonstrated  $K>0.85$  with similar methodology,<sup>2</sup> this study is powered at 80% to determine a  $K>0.80$  with a sample size of 48 with a null  $K$  value of 0.40.<sup>3</sup> However, due to the expected restriction of subjects in phases 2 and 3 of this study (to only those subjects with 100% agreement between raters to maintain the integrity of internal validity), doubling the required sample size is prudent to maintain power of the subsequent analyses.

## 2. Criteria for inclusion/exclusion

### *Rater Group*

**Inclusion criteria** will be state licensure as a physical therapist and regular clinical practice with patients with shoulder disorders, defined as a minimum of 500 clinical hours per year in an orthopaedic setting with >10% of patients with shoulder disorders. **Exclusion criteria** will include not meeting inclusion criteria.

### *Patient Group*

**Inclusion criteria** will be presenting with a chief complaint of shoulder pain, not extending to the neck, for outpatient physical therapy consultation. **Exclusion criteria** will include illiteracy in English and age less than 18 years. Additionally, subjects will be excluded from the study if they present with pain or symptoms distal to elbow, have had shoulder surgery on the symptomatic side in the past year, if active or passive cervical spine ROM reproduces shoulder pain, have a positive Spurling's test, or if they are unable to complete the patient reported functional questionnaires. Subjects found to have need for referral to another medical professional will be provided with the appropriate referral. If the reason for referral would prevent them from participating safely in the study, that subject will be excluded from testing.

### 3. Institutional Review Board (IRB) approval

Ethics approval has been obtained from the Institutional Review Boards of St. Luke's University Health Network (SLHN 2016-61) and Nova Southeastern University (2016-379). Written informed consent will be obtained from each subject prior to enrollment.

## Section C: Methods and Instrumentation

## **Instrumentation**

## Demographic information questionnaire

The survey will collect demographic data from raters including name, age, years of practice, advanced certification(s), gender, entry-level degree, and highest earned degree.

76        Shoulder Symptom Irritability Classification Scale

77        Raters will classify patient subjects in one of three shoulder symptom irritability  
78        levels based upon: pain level, presence of night or resting pain, onset of pain during  
79        motion, differences between active and passive range of motion, and level of disability.<sup>4-6</sup>

80        Patient-Reported Outcome Scales

81        Three patient-rated outcome scales will be administered for the purpose of  
82        enhancing generalizability, as there is no single gold standard patient-reported outcome  
83        scale for patients with shoulder pain.<sup>7,8</sup>

84        *Focus On Therapeutic Outcomes (FOTO)*

85        The FOTO scale<sup>9</sup> is a computerized adaptive test (CAT) and will be  
86        administered via iPad (iPad 2, Apple, Cupertino, CA) at each St. Luke's Physical  
87        Therapy clinic. The FOTO scale has been found to be a reliable and valid  
88        measurement system for outpatient orthopedic rehabilitation,<sup>9-11</sup> and has  
89        demonstrated good construct validity and responsiveness for patients with  
90        shoulder complaints.<sup>12,13</sup> The FOTO questionnaire has a low burden on patients,  
91        with a mean test administration time of 1 minute and 29 seconds (SD = 90  
92        seconds).<sup>12</sup> Furthermore, the standard error of the mean (SEM) has been found to  
93        be 1.30 with a minimal detectable change with 95% confidence (MDC<sub>95</sub>) of 3.60-  
94        10.88 functional score units.<sup>12,13</sup> Additionally, FOTO will be utilized to collect  
95        demographic data for each patient including comorbidities, age, gender, height,  
96        weight, chronicity of symptoms, type of insurance used, level of fear avoidance,  
97        and number of surgeries.

98        *Penn Shoulder Score (PSS)*

99        The Penn Shoulder Score (PSS), originally published in 1999<sup>14</sup> and  
100        validated in 2006,<sup>15</sup> is a self-report questionnaire consisting of three sections:  
101        pain, satisfaction, and function. The function subscale consists of twenty (20)  
102        items, each on a 4-point Likert scale. Each item is scored as 0 (can't do at all), 1  
103        (much difficulty), 2 (with some difficulty), or 3 (no difficulty). The item scores  
104        are then summed to determine the subscale score out of 60 (no difficulty for all  
105        items). Resultant scores for each subscale are divided by the total range from 0-  
106        100 with 0 as greatest disability and 100 as no disability.<sup>14</sup> The PSS has  
107        demonstrated good test-retest reliability (ICC<sub>2,1</sub> = 0.94) with a SEM<sub>90</sub> of 8.5.<sup>15</sup>  
108        The MDC<sub>90</sub> is 12.1, and the minimal clinically important difference (MCID) was  
109        found to be 11.4.<sup>15</sup>

110        *American Shoulder and Elbow Surgeons (ASES) Shoulder Score*

111        The American Shoulder and Elbow Surgeons (ASES) Shoulder Score,  
112        originally published in 1994<sup>16</sup> and validated in 2002,<sup>17</sup> is a self-report  
113        questionnaire consisting of two sections: one visual analog scale (VAS) to

114 measure pain, and ten items to measure activities of daily living. The  
115 questionnaire takes 3 minutes to complete and is scored as follows: [(10 – VAS  
116 pain) x 5] + (5/3 x sum of ADL items).<sup>18</sup> Resultant scores for each subscale range  
117 from 0-100 with 0 as greatest disability and 100 as no disability.<sup>18</sup> The ASES has  
118 demonstrated good to excellent test-retest reliability (ICC = 0.61-0.96) with an  
119 SEM of 6.7.<sup>18</sup> The MDC<sub>95</sub> is 11.2,<sup>17</sup> and the MCID was found to be 12.0.<sup>19</sup> A  
120 recent systematic review found the ASES to be one of the only patient-reported  
121 functional scales for rotator cuff disease to have measurement error below 10% of  
122 the global score.<sup>20</sup>

#### 123 Numeric Pain Rating Scale

124 The Numeric Pain Rating Scale (NPRS) is an 11-point Likert scale that can be  
125 used to measure pain intensity. The NPRS is a standard pain assessment scale that uses a  
126 0-10 scale (no pain to worst pain imaginable, respectively) in order to determine a  
127 patient's level of pain. Patients rate their current level of pain and their worst and least  
128 amount of pain in the last 24 hours. The average of the 3 ratings is used to represent the  
129 patient's level of pain. The NPRS has demonstrated good reliability (ICC<sub>2,1</sub>=0.74) and  
130 responsiveness (MDC = 2.5, MCID = 1.1) in subjects with shoulder pain<sup>21</sup> and excellent  
131 reliability in an upper extremity orthopaedic population.<sup>22</sup> Furthermore, the NPRS has  
132 been used to assess pain severity of both traumatic and atraumatic etiologies.<sup>23</sup>

#### 133 Range of Motion

134 Goniometric measurements of shoulder AROM in symptomatic patients  
135 demonstrates fair-good reliability with regards to intra- and inter-rater reliability (Inter-  
136 rater Rho = 0.64-0.80; Intra-rater Rho = 0.53-0.91).<sup>24-27</sup> Passive range of motion (PROM)  
137 demonstrates even greater reliability with intra-examiner ICC values = 0.98, and inter-  
138 examiner ICC values ranging from 0.87-0.89.<sup>25</sup>

#### 139 End Feel - Pain

140 The ability to utilize end feel to determine sequence of pain in relation to tissue  
141 resistance has generally shown good intra-rater reliability (K = 0.48 to 0.59,<sup>28</sup> K<sub>w</sub> = 0.59  
142 to 0.87<sup>29</sup>) and is frequently used for clinical decision-making.<sup>29</sup>

#### 143 Procedures

144 At least 2 raters will be recruited from each site. Raters will be trained with the following  
145 materials: (1) Collaborative Institutional Training Initiative (CITI) training for those involved in  
146 consenting the patients; (2) the reading of the Staged Approach for Rehabilitation Classification:  
147 Shoulder Disorders<sup>6</sup> with direction to pay special attention to the section on Level 3  
148 classification and Table 3;<sup>6(pp 795-6)</sup> and (3) a short online narrated presentation to reinforce  
149 understanding of the content. The intent of this training method is to increase the generalizability  
150 of the study results, and to avoid overly specialized training methods that would be difficult to  
151 reproduce clinically.

152        Patients will be recruited by the raters from their regular caseload (Appendix C). Patients  
153 will receive a brief explanation about the study, provide informed consent, and be asked to  
154 complete the functional questionnaires as part of the outpatient admissions process. The first  
155 therapist will rate the patient's shoulder symptom irritability level during the normal examination  
156 process utilizing the intake (Appendix C). Raters will inquire on the presence of night or resting  
157 pain and complete a physical examination including measurement of active and passive shoulder  
158 flexion. Range of motion measurements will be utilized for direct comparison and to determine  
159 the onset of pain during passive motion. Shoulder flexion will be measured utilizing goniometric  
160 procedures described elsewhere.<sup>24,25</sup> Active range of motion testing will be performed in  
161 standing and passive range of motion testing will be performed in supine.

162        After the first rater has completed their examination and prior to any intervention that  
163 may change the shoulder symptom irritability, a second rater, blinded from the first rater's  
164 assessment, will then examine and rate the subject (Appendix C). In addition to the shoulder  
165 symptom irritability rating, both raters will also be asked to provide a treatment intensity  
166 recommendation based upon the examination findings (Appendix C). Data collection forms will  
167 be placed in a sealed envelope and sent via interoffice mail for analysis. To maintain rater  
168 blinding, raters will be asked to not discuss ratings until data collection is complete.

#### 169 ***Data Collection and Storage***

170        Data will be collected for a period of 6 months. All data will be kept on a secure,  
171 password-protected server (RedCap, Nashville, TN; <https://redcap.slhn.org/>).

#### 172 ***Section D: Statistical Analysis***

173        Descriptive statistics will be used to characterize both raters and patients. Frequencies  
174 will be utilized for categorical variables, and means with standard deviations for continuous  
175 variables.

176        A repeated measures design, utilizing two raters per subject, will be utilized to determine  
177 inter-rater reliability. The raters will independently rate the subject's shoulder symptom  
178 irritability level utilizing the recently developed shoulder symptom irritability scale.<sup>4,6</sup> The inter-  
179 rater reliability will be evaluated using the PABAK-OS statistic.<sup>1,3</sup> For evaluation of statistical  
180 significance, a two-tailed confidence interval will be utilized with  $\alpha$  set to 0.05, and the null  
181 hypothesis will be that the PABAK-OS will be  $<0.40$ .<sup>3</sup>

182        Analysis of variance with post-hoc analysis will be utilized for evaluation of differences  
183 in patient reported functional limitation and pain subscales between shoulder symptom  
184 irritability groups. For evaluation of statistical significance,  $\alpha$  will be set to 0.05.

185        Lastly, to evaluate correlation between intervention intensity and diagnosed level of  
186 shoulder symptom irritability, the PABAK-OS statistic will be used. Additionally, independent t-  
187 tests will be utilized to evaluate for difference between groups for hypotheses 1 and 2 of aim 3.  
188 For evaluation of statistical significance,  $\alpha$  will be set to 0.05.

**189      Section E: Limitations and Potential Problems**

190      One potential problem is the need to have more than one clinician trained and available to  
191      rate the subjects at all times. Many clinics in this regional hospital network have fewer than  
192      three physical therapists and thus, there will be a risk of potential subject loss during the  
193      reliability phase. I intend to address this barrier via incentives derived from grant application  
194      and via administrative support as the hospital network has a defined educational and research  
195      vision.

196      A limitation to this study is the use of physical therapists and consecutive patients from a  
197      single regional hospital network. However, the regional hospital network encompasses over 30  
198      locations with over 80 physical therapists, 18 of which are clinical specialists. Furthermore, the  
199      need to have more than one clinician trained and available to rate the subjects at all times could  
200      potentially lead to subject loss during the reliability phase.

201      Another limitation of this study would be the limitation of data in aim 3 to only those  
202      subjects who had complete agreement between raters. This would potentially reduce the power  
203      of this part of the study. However, the risk to internal validity by utilizing the subjects without  
204      complete agreement would be a greater threat to the study than the limitation of power to aim 3  
205      and, to minimize the effect of this limitation, sample size will be twice the size needed to power  
206      the study at 80%.

207      Additionally, the FOTO functional status instrument is a proprietary measure, and while  
208      it is utilized nationally and internationally, it is not likely that it will be universally used due to  
209      its proprietary nature, thus limiting the generalizability of that aspect of the study. Finally, the  
210      data obtained regarding clinician outcome trends is retrospective rather than prospective. While  
211      longitudinal data would be ideal, the aim of utilizing retrospective data is to determine if further  
212      investigation utilizing longitudinal data is necessary, given the time and financial implications of  
213      such a study.

**APPENDIX A: IRB INFORMED CONSENT - SUBJECTS**

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

**St. Luke's University Health Network****Informed Consent Document for Human Subjects Research****Department:** Physical Therapy at St. Luke's**Principal Investigator:** Stephen Kareha, DPT      **Telephone:** 484-426-2544**Co-investigator:** Alicia Fernandez-Fernandez, DPT, PhD      **Telephone:** 954-262-1653**Co-investigator:** Philip McClure, PT, PhD      **Telephone:** 215-572-2863**Medical Study Title:** Shoulder Symptom Irritability: A Single-Blinded Observational Study**Lay Study Title:** Shoulder Symptom Irritability Testing**Sponsor:** None**What Is Informed Consent?**

You are being asked to take part in a medical research study. As required by federal regulations, this research study has been reviewed and approved by an Institutional Review Board (IRB), a committee that reviews, approves and monitors research involving humans. Before you can make a decision about whether to participate, you should understand the possible risks and benefits related to this study. This process of learning and thinking about a study before you make a decision is known as *informed consent* and includes:

- Receiving detailed information about this research study;
- Being asked to read, sign and date this consent form, once you understand the study and have decided to participate. If you don't understand something about the study or if you have questions, you should ask for an explanation before signing this form;
- Being given a copy of the signed and dated consent form to keep for your own records.

**What is the purpose of this study?**

Shoulder pain is a large medical and economic problem. Each person that is treated for shoulder pain has a unique case, however, research is continually being performed to try to help medical providers better treat these patients. One way we are trying to enhance this is by developing a tool for classifying the level of "shoulder symptom irritability," or pain and dysfunction levels, of patients with shoulder pain. This study is looking at the reliability (or accuracy) and use of this irritability scale between many different physical therapists.

**How many individuals will participate in the study and how long will the study last?**

258

259 90 patients will participate at St. Luke's University Health Network. Your involvement in the  
260 study will last about 1 day.

261

**262 What will I have to do during the study?**

263

264 Whether or not you choose to participate, your treatment and care will not change or be affected.  
265 Your physical therapist will still examine, evaluate, and treat you as they would regardless of  
266 participation in the study. Your involvement includes: answering your therapists questions in  
267 regards to pain levels, filling out a functional activity questionnaire, and discussing your  
268 condition with your physical therapist.

269

**270 What are the risks or discomforts involved?**

271

272 There are no side effects or risks for participating in the study and, as stated before, your  
273 treatment will not differ whether you choose to participate in the study or not.

274

**275 Are there alternatives to being in the study?**

276

277 You do not have to participate in this study.

278

**279 HIPAA Authorization: How will privacy and confidentiality (identity) be protected?**

280

281 Federal regulations require that certain information about individuals be kept confidential. This  
282 information is called "protected health information" (PHI). PHI includes information that  
283 identifies you personally such as name, address and social security number, or any medical or  
284 mental health record, or test result, that may have this sort of information on it. The laws state  
285 that you may see and review your St. Luke's University Health Network medical records at any  
286 time. However, in a research study, you may not see the study results or other data about the  
287 study until after the research is completed unless the study doctor decides otherwise.

288

289 If you join this study, the following individuals or entities may have access to your PHI and by  
290 law must protect it. These include investigators listed on this consent form and other personnel  
291 of St. Luke's University Health Network involved in this specific study, including the  
292 Institutional Review Board (IRB), and your health insurance company (if necessary for billing  
293 for standard medical care). It may also be provided to other people or groups as follows:

294

- 295 • Researchers at Arcadia University
- 296 • Researchers at Nova Southeastern University

297

298 Your PHI may also be shared with the following entities that, while not obligated by law to  
299 protect PHI, will protect it to the best of their ability:

300

- 301 • With any person or agency required by law.

302

303

304 The following information will be provided to the study sponsor and other entities noted above:

305

306 **Study data for analysis:** Questionnaire results and physical examination results

307 **Demographic data:** None

308

309 If you develop an illness or injury during the course of your participation in this study, other PHI  
310 about treating and following the condition may be generated and disclosed as it relates to this  
311 study. Your PHI may be used/disclosed until the end of the research study.

312

313

314 You may quit the study and revoke permission to use and share your PHI at any time by  
315 contacting the principal investigator, in writing, at: Dr. Stephen Kareha, 501 Cetronia Rd., Suite 145,  
316 Allentown, PA 18104. If you quit the study further collection of PHI will be stopped, but PHI that  
has already been collected may still be used.

317  
318 The results of clinical tests and procedures performed as part of this research may be included in  
319 your medical records. The information from this study may be published in scientific journals or  
320 presented at scientific meetings but you will not be personally identified in these publications and  
321 presentations.

322  
323 After your information is shared with others, like the sponsor, it may no longer be protected by  
324 the Privacy Rule. The people who receive this information could use it in ways not discussed in  
325 this form and could disclose it to others. The sponsor will use and disclose information about you  
326 only for research or regulatory purposes or to prepare research publications. In addition to using  
327 it for this study, the sponsor may reanalyze the study data at a later date or combine your  
328 information with information from other studies for research purposes not directly related to this  
329 study. When using the information in these ways, the sponsor may share it with other  
330 researchers, its business partners, or companies hired to provide research-related services.  
331 However, your name will never appear in any sponsor forms, reports, databases, or publications,  
332 or in any future disclosures by the sponsor.

333 A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required  
334 by U.S. Law. This Web site will not include information that can identify you. At most, this Web  
335 site will include a summary of the results. You can search this Web site at any time.

336  
337 **Will I benefit from being in this study?**

338  
339 You may not benefit from being in this research, but we hope that what we learn may be helpful  
340 to future patients or society in general.

341  
342 **Will I be paid for being in this study?**

343  
344 You will not receive payment for your participation in this study.

345  
346 In addition, you will not be paid if inventions and/or patents are developed from the study  
347 results.

348  
349 **Will I be told about any new findings?**

350  
351 Anything learned during the study, beneficial or not, that may affect your health or your  
352 willingness to continue in the study, will be told to you and explained.

353  
354 **Are there costs related to being in this study?**

355  
356 There are no costs associated with being in this study beyond normal physical therapy care.

357

**358 Can I be removed from the study or quit the study?**

359

360 Your decision to participate in this research study is entirely voluntary. You have been told what  
361 being in this study will involve, including the possible risks and benefits.

362

363 Your participation in this research project may be terminated by the study doctor without your  
364 consent for any reason that he/she feels is appropriate or if your pain is not primarily coming  
365 from your shoulder.

366

367 You may refuse to participate in this investigation or withdraw consent and quit this study  
368 without penalty and without affecting your ability to receive medical care at St. Luke's  
369 University Health Network.

370

371 If you withdraw from this study, you may continue treatment with your St. Luke's University  
372 Health Network doctor, or you may seek treatment from another doctor of your choice.

373

374 Should you decide to withdraw from the study, please be sure to inform the study doctor.  
375 Additional tests or procedures may be needed to ensure your safety. The study doctor will  
376 explain why these tests or procedures are necessary.

377

378

**379 CONTACT INFORMATION**

380

Telephone number for questions about your rights as a research participant	St. Luke's University Health Network Institutional Review Board	484-526-6742
For questions, concerns or complaints about the research, or if you suspect a research-related injury	The Principal Investigator, Dr. Stephen Kareha listed at the beginning of this form	484-426-2544

381

382 **By your agreement to participate in this study, and by signing this consent form, you are**  
383 **not waiving any of your legal rights.**  
384  
385 **You affirm that you have read this consent form, and have been told that you will receive a**  
386 **copy.**  
387  
388 **You also authorize the use and disclosure of your health information to the parties listed in**  
389 **the HIPAA authorization section of this consent for the purposes as described.**  
390  
391  
392  
393

394 Your Name (*please print or type*)

395 \_\_\_\_\_

396 Your Signature Date

397 \_\_\_\_\_

400 Name of Person Conducting  
401 Consent

402 \_\_\_\_\_

403 Signature of Person Conducting Date

404 \_\_\_\_\_

405 \_\_\_\_\_

406 \_\_\_\_\_

407 \_\_\_\_\_

408 \_\_\_\_\_

409 \_\_\_\_\_

410 \_\_\_\_\_

411 \_\_\_\_\_

**412 APPENDIX B: IRB INFORMED CONSENT - RATERS**

413

**414 St. Luke's University Health Network**  
**415 Informed Consent Document for Human Subjects Research**

416

**417 Department:** Physical Therapy at St. Luke's

418

**419 Principal Investigator:** Stephen Kareha, DPT **Telephone:** 484-426-2544

420

**421 Co-investigator:** Alicia Fernandez-Fernandez, DPT, PhD **Telephone:** 954-262-1653

422

**423 Co-investigator:** Philip McClure, PT, PhD **Telephone:** 215-572-2863

424

**425 Medical Study Title:** Shoulder Symptom Irritability: A Single-Blinded Observational Study

426

**427 Lay Study Title:** Shoulder Symptom Irritability Testing

428

**429 Sponsor:** None

430

431

**432 What Is Informed Consent?**

433

434 You are being asked to take part in a medical research study. As required by federal regulations,  
435 this research study has been reviewed and approved by an Institutional Review Board (IRB), a  
436 committee that reviews, approves and monitors research involving humans. Before you can make  
437 a decision about whether to participate, you should understand the possible risks and benefits  
438 related to this study. This process of learning and thinking about a study before you make a  
439 decision is known as *informed consent* and includes:

440 • Receiving detailed information about this research study;  
441 • Being asked to read, sign and date this consent form, once you understand the study and  
442 have decided to participate. If you don't understand something about the study or if you  
443 have questions, you should ask for an explanation before signing this form;  
444 • Being given a copy of the signed and dated consent form to keep for your own records.

445

**446 What is the purpose of this study?**

447

448 Shoulder pain is a large medical and economic problem. Each person that is treated for shoulder  
449 pain has a unique case, however, research is continually being performed to try to help medical  
450 providers better treat these patients. One way we are trying to enhance this is by developing a  
451 tool for classifying the level of "shoulder symptom irritability," or pain and dysfunction levels,  
452 of patients with shoulder pain. This study is looking at the reliability (or accuracy) and use of this  
453 irritability scale between many different physical therapists.

454

**455 How many individuals will participate in the study and how long will the study last?**

456

457 25 raters will participate at St. Luke's University Health Network. Your involvement in the study  
458 will last about 6 months.

459

**460 What will I have to do during the study?**

461

462 Whether or not you choose to participate, your employment and eligibility for promotion will not  
463 change or be affected. Your involvement includes: reading of the Staged Approach for  
464 Rehabilitation Classification: Shoulder Disorders with special focus on the section regarding  
465 Level 3 classification and Table 3, a short online narrated presentation to reinforce understanding  
466 of the content, and completing rating forms for patients with shoulder pain.

467

**468 What are the risks or discomforts involved?**

469

470 There are no side effects or risks for participating in the study and, as stated before, your  
471 employment and eligibility for promotion will not differ whether you choose to participate in the  
472 study or not.

473

**474 Are there alternatives to being in the study?**

475

476 You do not have to participate in this study.

477

**478 HIPAA Authorization: How will privacy and confidentiality (identity) be protected?**

479

480 Federal regulations require that certain information about individuals be kept confidential. This  
481 information is called "protected health information" (PHI). PHI includes information that  
482 identifies you personally such as name, address and social security number, or any medical or  
483 mental health record, or test result, that may have this sort of information on it. The laws state  
484 that you may see and review your St. Luke's University Health Network medical records at any  
485 time. However, in a research study, you may not see the study results or other data about the  
486 study until after the research is completed unless the study doctor decides otherwise.

487

488 If you join this study, the following individuals or entities may have access to your PHI and by  
489 law must protect it. These include investigators listed on this consent form and other personnel  
490 of St. Luke's University Health Network involved in this specific study, including the  
491 Institutional Review Board (IRB), and your health insurance company (if necessary for billing  
492 for standard medical care). It may also be provided to other people or groups as follows:

493

- 494 • Researchers at Arcadia University
- 495 • Researchers at Nova Southeastern University

496

497 Your PHI may also be shared with the following entities that, while not obligated by law to  
498 protect PHI, will protect it to the best of their ability:

499

500 • With any person or agency required by law.

501

502 The following information will be provided to the study sponsor and other entities noted above:

503

504 **Study data for analysis:** Questionnaire results and physical examination results

505 **Demographic data:** None

506

507 If you develop an illness or injury during the course of your participation in this study, other PHI  
508 about treating and following the condition may be generated and disclosed as it relates to this  
509 study. Your PHI may be used/disclosed until the end of the research study.

510

511 You may quit the study and revoke permission to use and share your PHI at any time by  
512 contacting the principal investigator, in writing, at: Dr. Stephen Kareha, 501 Cetronia Rd., Suite 145,  
513 Allentown, PA 18104. If you quit the study further collection of PHI will be stopped, but PHI that  
514 has already been collected may still be used.

515

516 The results of clinical tests and procedures performed as part of this research may be included in  
517 your medical records. The information from this study may be published in scientific journals or  
518 presented at scientific meetings but you will not be personally identified in these publications and  
519 presentations.

520

521 After your information is shared with others, like the sponsor, it may no longer be protected by  
522 the Privacy Rule. The people who receive this information could use it in ways not discussed in  
523 this form and could disclose it to others. The sponsor will use and disclose information about you  
524 only for research or regulatory purposes or to prepare research publications. In addition to using  
525 it for this study, the sponsor may reanalyze the study data at a later date or combine your  
526 information with information from other studies for research purposes not directly related to this  
527 study. When using the information in these ways, the sponsor may share it with other  
528 researchers, its business partners, or companies hired to provide research-related services.  
529 However, your name will never appear in any sponsor forms, reports, databases, or publications,  
530 or in any future disclosures by the sponsor.

531

532 A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required  
533 by U.S. Law. This Web site will not include information that can identify you. At most, this Web  
534 site will include a summary of the results. You can search this Web site at any time.

535

536 **Will I benefit from being in this study?**

537

538 You may not benefit from being in this research, but we hope that what we learn may be helpful  
539 to future patients or society in general.

540

541 **Will I be paid for being in this study?**

542

543 You will receive payment for your participation in this study. You will receive a \$5 gift  
544 certificate for each patient you rate in this study. Should study payments meet or exceed \$600 in  
545 one calendar year, you will be issued a 1099 Form to report study payments as taxable income as  
546 required by the IRS. ***We do not foresee your participation falling under the reportable income  
547 parameters as there are only a total of 90 study subjects being enrolled, thus the maximum you  
548 will be paid for your participation is \$450.***

549

550

551 In addition, you will not be paid if inventions and/or patents are developed from the study  
552 results.

553

554 **Will I be told about any new findings?**

555

556 Anything learned during the study, beneficial or not, that may affect your health or your  
557 willingness to continue in the study, will be told to you and explained.

558

559 **Are there costs related to being in this study?**

560

561 There are no costs associated with being in this study beyond normal physical therapy practice.

562

563 **Can I be removed from the study or quit the study?**

564

565 Your decision to participate in this research study is entirely voluntary. You have been told what  
566 being in this study will involve, including the possible risks and benefits.

567

568 Your participation in this research project may be terminated by the study doctor without your  
569 consent for any reason that he/she feels is appropriate or if your pain is not primarily coming  
570 from your shoulder.

571

572 You may refuse to participate in this investigation or withdraw consent and quit this study  
573 without penalty and without affecting your ability to receive medical care at St. Luke's  
574 University Health Network.

575

576 If you withdraw from this study, you may continue treatment with your St. Luke's University  
577 Health Network doctor, or you may seek treatment from another doctor of your choice.

578

579 Should you decide to withdraw from the study, please be sure to inform the study doctor.  
580 Additional tests or procedures may be needed to ensure your safety. The study doctor will  
581 explain why these tests or procedures are necessary.

582

583

**584 CONTACT INFORMATION**

585

Telephone number for questions about your rights as a research participant	St. Luke's University Health Network Institutional Review Board	484-526-6742
For questions, concerns or complaints about the research, or if you suspect a research-related injury	The Principal Investigator, Dr. Stephen Kareha listed at the beginning of this form	484-426-2544

**By your agreement to participate in this study, and by signing this consent form, you are not waiving any of your legal rights.**

**You affirm that you have read this consent form, and have been told that you will receive a copy.**

**You also authorize the use and disclosure of your health information to the parties listed in the HIPAA authorization section of this consent for the purposes as described.**

\_\_\_\_\_  
Your Name (*please print or type*)

\_\_\_\_\_  
Your Signature

\_\_\_\_\_  
Date

\_\_\_\_\_  
Name of Person Conducting  
Consent

\_\_\_\_\_  
Signature of Person Conducting  
Consent

\_\_\_\_\_  
Date

## APPENDIX C: SURVEYS AND DATA COLLECTION FORMS



Subject # \_\_\_\_\_

### Rater Information

Name: \_\_\_\_\_

Age: \_\_\_\_\_

Years of Practice: \_\_\_\_\_

#### Advanced Certifications Held:

- OCS
- SCS
- FAAOMPT
- Other \_\_\_\_\_

Gender:  Male  Female

#### Entry Level Degree:

- BS
- MS
- DPT

#### Highest Earned Degree:

- BS
- MS
- DPT
- PhD, ScD, EdD



For Office Use Only:  
Subject # \_\_\_\_\_

Inclusion Criteria

- 18 years old or older
- Chief complaint of shoulder pain

Exclusion Criteria

- Pain or symptoms distal to the elbow
- History of ipsilateral shoulder surgery
- Active or passive cervical spine ROM reproduces shoulder pain
- Positive Spurling's test
- Not literate in the English language
- Unable to complete the self-report functional questionnaires

- Subject meets BOTH inclusion criteria AND does not meet ANY of the exclusion criteria
- Subject does NOT meet inclusion criteria OR meets one of the exclusion criteria

PENN/ASES SHOULDER SCORE								
Subject #								
Dominant Hand:			Gender:			Affected Arm:		
L	R	Both	M	F	(circle one)	L	R	Both
PENN SHOULDER SCORE								
Part I: Pain & Satisfaction: Please circle the number closest to your level of pain or satisfaction								
How bad is your pain today?								
0	1	2	3	4	5	6	7	8
No								
Pain								
								10
								Worst
								Pain Possible
ASES Pain _____ (10 - # circled + ___ x 5 = ___)								
Pain at rest with your arm by your side:								
0	1	2	3	4	5	6	7	8
No								
Pain								
								10
								Worst
								Pain Possible
ASES Pain _____ (10 - # circled + ___ x 5 = ___)								
Pain with normal activities (eating, dressing, bathing):								
0	1	2	3	4	5	6	7	8
No								
Pain								
								10
								Worst
								Pain Possible
ASES Pain _____ (10 - # circled + ___ x 5 = ___)								
Pain with strenuous activities (reaching, lifting, pushing, pulling, throwing):								
0	1	2	3	4	5	6	7	8
No								
Pain								
								10
								Worst
								Pain Possible
ASES Pain _____ (10 - # circled + ___ x 5 = ___)								
PAIN SCORE: = ___ /30								
How satisfied are you with the <u>current</u> <u>level of function</u> of your shoulder?								
0	1	2	3	4	5	6	7	8
Not								
Satisfied								
								10
								Very
								Satisfied
ASES Satisfaction _____ (# circled)								

PLEASE TURN OVER TO COMPLETE  
QUESTIONNAIRE

---

OFFICE USE ONLY

Today's Date: / /		
	PENN SHOULDER SCORE (PSS)	ASES SHOULDER SCORE (ASES)
Pain	/30	/50
Satisfaction	/10	
Function	/60	/50
<b>TOTAL</b>	/100	/100

© 1998 Brian G. Leggin

\*\*The author grants unrestricted use of this questionnaire for patient care and clinical research purposes.

PENN SHOULDER SCORE/ASES SHOULDER SCORE Part II: Function: Please circle the number that best describes the level of difficulty you might have performing each activity.		No difficulty	Some difficulty	Much difficulty	Can't do at all	Did not do before injury
1. Reach the small of your back to tuck in your shirt with your hand.	3	2	1	0	X	
2. Wash the middle of your back/hook bra. (ASES #3)	3	2	1	0	X	
3. Perform necessary toileting activities. (ASES #4)	3	2	1	0	X	
4. Wash the back of opposite shoulder.	3	2	1	0	X	
5. Comb hair. (ASES #5)	3	2	1	0	X	
6. Place hand behind head with elbow held straight out to the side.	3	2	1	0	X	
7. Dress self (Including put on coat and pull shirt over head. (ASES #1)	3	2	1	0	X	
8. Sleep on affected side. (ASES #2)	3	2	1	0	X	
9. Open a door with affected side.	3	2	1	0	X	
10. Carry a bag of groceries with affected arm.	3	2	1	0	X	
11. Carry a briefcase/small suitcase with affected arm.	3	2	1	0	X	
12. Place a soup can (1-2 lbs.) on a shelf at shoulder level without bending elbow.	3	2	1	0	X	
13. Place a one gallon container (8-10 lbs.) on a shelf at Shoulder level without bending elbow.	3	2	1	0	X	
14. Reach a shelf above your head without bending your elbow. (ASES #6)	3	2	1	0	X	
15. Place a soup can (1-2 lbs.) on a shelf overhead without bending your elbow.	3	2	1	0	X	
16. Place a one gallon container (8-10 lbs.) on a shelf Overhead without bending your elbow. (ASES #7)	3	2	1	0	X	
17. Perform usual sport/hobby. (ASES #8)	3	2	1	0	X	
18. Perform household chores (cleaning, laundry, cooking).	3	2	1	0	X	
19. Throw overhand/swim/overhead racquet sports. (circle all that apply to you) (ASES #8)	3	2	1	0	X	
20. Work full-time at your regular job. (ASES #10)	3	2	1	0	X	
<b>SCORING:</b> (office use only)	PSS	PSS	PSS	PSS	PSS	
PSS Total of all columns = _____ (a)	_____	_____	_____	_____	_____	
Number of "X's" x 3 = _____ (b), 80 - _____ (b) = _____ (c)	_____	_____	_____	_____	_____	
(If no "X's" are circled, function score = total of columns)	ASES	ASES	ASES	ASES		
PSS Function Score = _____(a) + _____(c) = _____ x 80 = _____ of 80	_____	_____	_____	_____		
ASES Score = _____						
Total of shaded columns: _____ x 5/3 = _____ of 60						


Physical Therapy at St. Lukes - Physical Therapy at St. Luke's - West End  
INTAKE FUNCTIONAL STATUS SUMMARY

Patient:	Risk-Adjustment Criteria			
ID#:			Gender:	
Date of Birth:			Comorbidities:	
Initial DOS:			Payer:	
Body Part:		Severity:		
Impairment:		Age:		
Surgery Type:		Acuity:		
Surgery Date:				

Functional Status Measures:	Intake Score	Interpretation of FS Scores/Stages Value
Patient's Physical FS Primary Measure		Patient's Intake functional measure is out of (higher number = greater function). This FS measure places the patient in Stage 4 and means the patient has good shoulder function.
Risk Adjusted Statistical FOTO*		Given the patient's risk-adjustment variables, like-patients nationally had a FS score of 52, Stage 3, at Intake.

MCII = Points of change that is important to the patient)

MDC = Represents the smallest threshold to identify points of change that is greater than measurement error)



Rehabilitation Resource Predictor*	Predicted Value	Interpretation of Predicted Value
Points of Physical FS Change		
Discharge FS Score		Given this patient's risk-adjustment variables, and the actual Intake FS score, FOTO predicts this patient will experience at least an increase in function of 6 points (to 73 or higher), putting them in the Stage 4 level or higher at discharge.
Visits per Episode		Stage: 1 Exceedingly limited shoulder Stage: 2 Poor shoulder Stage: 3 Fair shoulder Stage: 4 Good shoulder Stage: 6 Excellent shoulder
Duration of Episodes in Days		
Satisfaction Score		

\* The above predictions are calculated for  
 1) patients who have previously utilized rehabilitation services from FOTO's national aggregate database and  
 2) using sophisticated analyses to risk adjust for the impact of ten important variables known to influence outcomes including Care type, Body Part/Impairment, Severity, Age, Acuity, Gender, Surgery, Payer, and Comorbidities.

## What Does This Mean For Improving Function

This chart displays the patient responses to the functional activities contained in the intake survey that generated the intake FS score. The activities are presented in the descending order of difficulty. Responses listed in the Intake column are the survey item levels of ability at intake. Given the change experienced by the comparative risk adjusted group in FOTO's data, it is anticipated the patient should be able to do the activities at the level indicated in the predicted column or higher at the completion of care, to place the patient in the predicted Stage 4 functional level by discharge.

## Patient responses to functional health questions that indicate dysfunction were as follows:

Activity (Question)	Amount of Limitation (Response) at Intake	Amount of Limitation (Response) predicted	Functional Limitation
How much difficulty do you have using your affected arm to place a 50 lb. box on a shelf overhead?			Other PT/OT Primary - G8990
How much difficulty do you have using your affected arm to place a 25 lb. box on a shelf overhead?	---		Other PT/OT Primary - G8990
Work overhead for more than 2 minutes?			Other PT/OT Primary - G8990

## Physical Therapy at St. Luke's - Physical Therapy at St. Luke's - West End

## INTAKE FUNCTIONAL STATUS SUMMARY

Patient:

Primary Body Part: Shoulder

Initial DOB:

## Patient responses to functional health questions that indicate dysfunction were as follows:

Touch an object on the back seat while sitting in the front seat of a car?			Carrying, Moving & Handling Objects - G8984 Other PT/OT Primary - G8990
Reach an overhead shelf?			Other PT/OT Primary - G8990
Reach a shelf that is at shoulder height?			Carrying, Moving & Handling Objects - G8984

If the patient reaches the anticipated level on the above activities, other Stage 4 activities the patient should be able to perform include:

- Adjusting the back of your collar with your affected hand - No difficulty
- Combing or brushing your hair using your affected arm - No difficulty
- Pull a medium weight object (5-10 lbs) from under a bed - No difficulty
- Move a heavy skillet (eg, cast iron skillet) from one stove burner to another - No difficulty
- Steady a jar while you loosen the jar lid - No difficulty
- Taking off glasses or sunglasses using your affected arm - No difficulty
- Place a can of soup (1 lb) on a shelf at shoulder height - No difficulty
- Reaching across to the middle of the table with your affected arm to get a salt shaker while sitting - No difficulty
- Turn a steering wheel in the opposite direction as your affected arm (eg, turn left if it is your right shoulder that is affected) - No difficulty
- Reach and pull the string that controls a light or fan - No difficulty

## Additional Intake Information Gathered for the Clinician

- Physician Referral: Insurance Referral:
- Patient reports other health problems as:
- BMI:
- Exercise prior to onset:
- Prescription medicine:
- Surgery:
- Fear avoidance belief about physical activity:

## Additional Surveys

Intake      Scale

Physical Fear

## Physical Fear

## Physical Fear Results:

Fear Avd  
Belief About  
Phys Activ

Intake

## Crosswalk

Intake      Scale

DASH

Mathematical crosswalk from the Shoulder FOS score to the DASH. For the DASH, a higher score indicates greater disability.

## Physical Therapy at St. Lukes - Physical Therapy at St. Luke's - West End

## INTAKE FUNCTIONAL STATUS SUMMARY

Patient:

Primary Body Part: Shoulder

Initial DOB:

## Pain Assessment Summary

## Intensity

In the last 24 hours the level of pain was rated at: /10  
 In the last 30 days, the level of least pain was rated at: /10  
 and the level of most pain was rated at: /10

## Character

Qualities of Pain  
Patient reports that the pain feels      The intensity is

Influence of Activity  
The pain is increased by      The pain is reduced by

## CMS G-Codes

## FOTO Shoulder Survey

CMS G-Code Options\*\*

## Functional Limitations Assessed in FOTO Shoulder Survey

Current Status	Goal Status	D/C*	Asked	Descriptor
G8984	G8985	G8986	2	Carrying, moving & handling objects functional limitation
G8987	G8988	G8989	0	Self care functional limitation
G8990	G8991	G8992	5	Other physical or occupational primary functional limitation

\*Only report if this is a one time visit.

## CMS Impairment/Limitation/Restriction for FOTO Shoulder Survey

Status	Limitation	G-Code	CMS Severity Modifier
Intake			
Predicted			

\*Based on FOTO predicted change score

X

Clinician:

\* Mean, Risk Adjusted, Intake Composite FS measures from FOTO aggregate database

\*\* As indicated by the ICF assignments to the survey items in the FOTO survey used.



For Office Use Only:  
Subject # \_\_\_\_\_

**Pain At Night or At Rest**

- Constantly
- Intermittently
- None

**AROM compared to PROM**

- AROM less than (<) PROM
- AROM nearly equal to (≈) PROM
- AROM equal to (=) PROM

**Pain reproduction with ROM**

- Prior to end range
- At end range
- None or with overpressure at end range



For Office Use Only:  
Subject # \_\_\_\_\_

**Irritability Rating**

Based upon your examination of this patient, please rate the level of shoulder symptom irritability:

High

Moderate

Low

Unclassifiable (Reason: \_\_\_\_\_)



For Office Use Only:

Subject # \_\_\_\_\_

**Which of the below treatments strategies would****BEST be used for this patient TODAY?**

(Select only one)

- Provide moderate–high physical stress**  
Address specific impairments  
Restore of high-demand functional activity
  
- Provide mild–moderate physical stress**  
Address specific impairments  
Restore basic-level functional activity
  
- Minimize Physical Stress**  
Modify activities  
Monitor impairments



For Office Use Only:  
Subject # \_\_\_\_\_

**Do you plan to provide any of the below treatments to this patient TODAY?**

1. Exercises addressing muscular weakness       Yes       No

If yes, select one option below:

- Active range of motion (no external load)
- Mild-moderate resistive strength training
- Moderate-high resistive strength training

2. Exercises addressing mobility       Yes       No

If yes, select one option below:

- Range of motion exercises (non-end range stress; pain free)
- Range of motion exercises (end range stress; transient or shorter hold times)
- Range of motion exercises (end range stress; longer duration hold times)

3. Shoulder joint mobilizations       Yes       No

If yes, select one option below:

- Low grade; not achieving end range
- High grade; achieving end range

4. Electrical Agents for pain control (e.g. TENS)       Yes       No

5. Thermal modalities       Yes       No

If yes, select one option below:

- For pain control or relaxation
- To facilitate tissue extensibility

6. Recommendations for Functional Activity       Yes       No

If yes, select one option below:

- Avoid provocative functional activities
- Encourage basic-level functional activities
- Encourage high-demand functional activities